Stem cells in baby urine to treat kidney disease

March 7, 2016 News BioVox

Patients with a kidney disease or injury can sometimes be helped with a specific type of stem cells. An international team led by Professor Elena Levtchenko from KU Leuven has now discovered that the urine of premature babies abounds with these cells. 

Kidney stem cells or kidney progenitors have not yet developed into mature cells with fixed functions in the kidney. Therefore, they can be vital for patients with failing kidneys. However, kidney stem cells are difficult to find. The urine of adults, for instance, contains barely any ‘original’ kidney cells.

The team of Professor Levtchenko has now discovered that these kidney stem cells are abundant in the urine of premature babies. Human kidneys are fully developed by the 34th week of the pregnancy. In children born before that time, the process is not yet fully complete, and many kidney stem cells are still present.

“We took urine samples from premature babies, one day after they were born. In 50% of the samples, we found kidney progenitors”, says Professor Levtchenko from the KU Leuven Organ Systems Unit. “We made these cells develop into mature kidney cells, which have different functions in the kidney.”

This discovery is not just good news for patients with a kidney disease or injury: the premature babies themselves, too, may benefit from it. Children who are born prematurely have an increased risk of kidneys that fail to adequately filter waste products from the blood. A treatment with the original cells could help these new-borns. Further research will have to show whether this is indeed the case.

(Source: KU Leuven)

Reference
Arcolina et al., Urine of Preterm Neonates as a Novel Source of Kidney Progenitor Cells, JASN, 2016


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter